Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults

This publication has 57 references indexed in Scilit:

• Humoral and cellular immunity to RSV in infants, children and adults
  Vaccine, 2018
• Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines
  JAMA, 2016
• Respiratory Syncytial Virus Infection in Older Adults: An Under-Recognized Problem
  Drugs & Aging, 2015
• AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial
  The Lancet Infectious Diseases, 2013
• Response definition criteria for ELISPOT assays revisited
  Cancer Immunology, Immunotherapy, 2010
• Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
  Published by Elsevier ,2008
• Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME–TRAP in 1–6 year old children in a malaria endemic area
  Vaccine, 2006
• Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
  JAMA, 2003
• Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy
  Vaccine, 2002
• Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults
  Journal of Medical Virology, 1999